BACKGROUND: Orbital fibroblast proliferation and hyaluronic acid (HA) release are responsible for some of the clinical features of Graves' ophthalmopathy (GO). Thus, inhibition of these processes may be a possible therapeutic approach to this syndrome. Enalapril, a widely used antihypertensive drug, was found to have some inhibitory actions on fibroblast proliferation in cheloid scars in vivo, based on which we investigated its effects in primary cultures of orbital fibroblasts from GO patients and control subjects. METHODS: Primary cultures of GO and control fibroblasts were treated with enalapril or with a control compound (lisinopril). Cell proliferation assays, lactate dehydrogenase release assays (as a measure of cell necrosis), apoptosis assays, and measurement of HA in the cell media were performed. RESULTS: Enalapril significantly reduced cell proliferation in both GO and control fibroblasts. Because enalapril did not affect cell necrosis and apoptosis, we concluded that its effects on proliferation reflected an inhibition of cell growth and/or a delay in cell cycle. Enalapril significantly reduced HA concentrations in the media from both GO and control fibroblasts. CONCLUSIONS: Enalapril has antiproliferative and HA suppressing actions in both GO and control fibroblasts. Clinical studies are needed to investigate whether enalapril has any effects in vivo in patients with GO.
|Autori:||Botta R; Lisi S; Marcocci C; Sellari-Franceschini S; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Sisti E; Casini G; Nardi M; Pinchera A; Vitti P; Marino' M|
|Titolo:||Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts|
|Anno del prodotto:||2013|
|Digital Object Identifier (DOI):||10.1089/thy.2012.0373|
|Appare nelle tipologie:||1.1 Articolo in rivista|